Table 4.
Characteristics | Metastasis timeline | ||||
---|---|---|---|---|---|
< 5 years | >5 years | p | |||
N | % | N | % | ||
Tumour size | |||||
<2 cm | 37 | 21.8 | 27 | 42.9 | 0.001 |
≥2 | 133 | 78.2 | 36 | 57.1 | |
Tumour grade | |||||
1 | 17 | 8.5 | 7 | 10.6 | |
2 | 99 | 49.3 | 42 | 63.6 | 0.056 |
3 | 85 | 42.3 | 17 | 25.8 | |
ER | |||||
Negative | 73 | 37.4 | 10 | 15.2 | |
Positive | 122 | 62.6 | 56 | 84.8 | 0.001 |
PR | |||||
Negative | 83 | 41.9 | 12 | 17.6 | |
Positive | 115 | 58.1 | 56 | 82.4 | <0.001 |
Tumour subtype | |||||
ER(−) HER2(−) | 52 | 30.8 | 7 | 13.5 | |
ER(+) HER2(−) Ki67high | 50 | 29.6 | 25 | 48.1 | |
ER(+) HER2(−) Ki67low | 17 | 10.1 | 9 | 17.3 | 0.003 |
ER(+) HER2(+) | 29 | 17.2 | 8 | 15.4 | |
ER(−) HER2(+) | 21 | 12.4 | 3 | 5.8 |
ER oestrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor